Jilin-based Chinese pharmaceutical company; specific product lines not fully confirmed from available knowledge.
Jilin-based Chinese pharmaceutical company; specific product lines not fully confirmed from available knowledge.
Moat: none
Headquarters: Tonghua, Jilin, China · Employees: 1,480
Size Tonghua Golden-Horse Pharmaceutical Industry (000766.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.62B, the 1414th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.03 on 18 Nov 2026.
Performance Over six months the shares fell 47.3%, against -3.7% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue fell 17.9% over the last twelve months (peer median +6.8%); the operating margin is 8.6% (peer median 12.0%).
Valuation It trades at 12.2× enterprise value to sales against a peer median of 4.5× (3rd most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +32 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.7 points below its cost of capital (5.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.01B | CN¥1.16B | CN¥1.31B | CN¥1.47B | CN¥1.46B |
| Revenue growth | — | -12% | -11% | 0% | — |
| Gross profit | CN¥763M | CN¥802M | CN¥948M | CN¥1.06B | CN¥1.08B |
| EBITDA | n/a | CN¥172M | CN¥203M | CN¥199M | CN¥189M |
| Net income | CN¥11.3M | CN¥34.3M | CN¥56.4M | CN¥43.9M | CN¥30.2M |
| Free cash flow | CN¥52.0M | CN¥41.0M | CN¥114M | CN¥86.1M | CN¥174M |
| Capital expenditure | CN¥38.1M | CN¥64.1M | CN¥49.2M | CN¥26.7M | CN¥23.7M |
| Total debt | CN¥2.03B | CN¥1.81B | CN¥1.80B | CN¥1.71B | CN¥1.80B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000766.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.6% | -3.8% | 3rd lowest of 21 |
| 6-month return | -47.3% | -3.7% | 2nd lowest of 20 |
| Distance from 52-week high | -60.2% | -33.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | -17.9% | +6.8% | 4th lowest of 20 |
| Operating margin | 8.6% | 12.0% | 8th lowest of 20 |
| EV / Sales | 12.2× | 4.5× | 3rd most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 33.0% | 11.3% | 3rd most demanding of 16 |
| Growth delivered (Del g) | +0.9% | +9.2% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | +32.0 pp | +7.6 pp | 2nd most demanding of 16 |
| ROIC minus cost of capital | -2.7 pp | +0.6 pp | 9th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | 12.2× | 33.0% | +0.9% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | 5.6× | 42.4% | +23.0% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 7.2× | n/a | n/a |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 9.8× | 31.1% | -15.1% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 5.2× | 12.8% | -14.0% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 1.2× | -6.6% | -5.6% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 2.2× | -14.9% | +13.5% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 2.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 4.5× | 6.0% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 2.5× | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 8.9× | 18.4% | +10.8% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% | +32.4% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 3.6× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 2.3× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 6.3× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 16.7× | 11.3% | -11.0% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 2.6× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | 68.8× | n/a | n/a |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 9.7× | 35.3% | +9.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 1.4× | -6.1% | +1.9% |